These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 32564642)

  • 1. Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
    Brandts J; Ray KK
    Expert Opin Investig Drugs; 2020 Aug; 29(8):763-770. PubMed ID: 32564642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Bempedoic Acid in Clinical Practice.
    Ballantyne CM; Bays H; Catapano AL; Goldberg A; Ray KK; Saseen JJ
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):853-864. PubMed ID: 33818688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bempedoic Acid: a cholesterol lowering agent with a novel mechanism of action.
    Nguyen H; Akamnonu I; Yang T
    Expert Rev Clin Pharmacol; 2021 May; 14(5):545-551. PubMed ID: 33691561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
    Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
    J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Greater than expected reduction in low-density lipoprotein-cholesterol (LDL-C) with bempedoic acid in a patient with heterozygous familial hypercholesterolemia (HeFH).
    Agha AM; Jones PH; Ballantyne CM; Virani SS; Nambi V
    J Clin Lipidol; 2021; 15(5):649-652. PubMed ID: 34393074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
    Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
    Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
    Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
    N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bempedoic Acid in the Treatment of Patients with Dyslipidemias and Statin Intolerance.
    Susekov AV; Korol LA; Watts GF
    Cardiovasc Drugs Ther; 2021 Aug; 35(4):841-852. PubMed ID: 33502687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bempedoic Acid: A New Drug for an Old Problem.
    Nguyen D; Du N; Sulaica EM; Wanat MA
    Ann Pharmacother; 2021 Feb; 55(2):246-251. PubMed ID: 32674598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
    Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
    Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids.
    Paton DM
    Drugs Today (Barc); 2020 Sep; 56(9):573-582. PubMed ID: 33025951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
    Bilen O; Ballantyne CM
    Curr Atheroscler Rep; 2016 Oct; 18(10):61. PubMed ID: 27663902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.
    Cicero AFG; Fogacci F; Cincione I
    Expert Opin Drug Metab Toxicol; 2021 Sep; 17(9):1031-1038. PubMed ID: 34197267
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
    Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
    JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside.
    Agarwala A; Quispe R; Goldberg AC; Michos ED
    Drug Des Devel Ther; 2021; 15():1955-1963. PubMed ID: 34007155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bempedoic acid. Mechanism of action and pharmacokinetic and pharmacodynamic properties.
    Masana Marín L; Plana Gil N
    Clin Investig Arterioscler; 2021 May; 33 Suppl 1():53-57. PubMed ID: 33966814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bempedoic acid (Nexletol) for lowering LDL-cholesterol.
    Med Lett Drugs Ther; 2020 Apr; 62(1595):53-55. PubMed ID: 32324179
    [No Abstract]   [Full Text] [Related]  

  • 18. Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials.
    Bays HE; Banach M; Catapano AL; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Bloedon LT; Sasiela WJ; Ye Z; Ballantyne CM
    J Clin Lipidol; 2020; 14(5):649-659.e6. PubMed ID: 32980290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor: Review of a First-in-Class Medication with Potential Benefit in Statin-Refractory Cases.
    Zagelbaum NK; Yandrapalli S; Nabors C; Frishman WH
    Cardiol Rev; 2019; 27(1):49-56. PubMed ID: 29939848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
    Rubino J; MacDougall DE; Sterling LR; Kelly SE; McKenney JM; Lalwani ND
    J Clin Lipidol; 2021; 15(4):593-601. PubMed ID: 34172394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.